Agendia plans to raise €75m by going public
This article was originally published in Clinica
Dutch firm Agendia today launched its initial public offering on the NYSE Euronext stock exchange in Amsterdam, aiming to raise up to €75m ($109.6m). The cancer molecular diagnostics specialist plans to use the funds to expand its sales and marketing activities in the US, where it currently markets four breast cancer tests in its Symphony product line.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.